In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Augmedix Inc (NASDAQ: AUGX) closed at $2.34 up 5.17% from its previous closing price of $2.22. In other words, the price has increased by $5.17 from its previous closing price. On the day, 0.56 million shares were traded. AUGX stock price reached its highest trading level at $2.37 during the session, while it also had its lowest trading level at $2.23.
Ratios:
For a deeper understanding of Augmedix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.41 and its Current Ratio is at 2.41. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 0.83.
On December 15, 2023, Evercore ISI started tracking the stock assigning a In-line rating and target price of $6.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when Shakil Ian sold 500 shares for $3.80 per share. The transaction valued at 1,900 led to the insider holds 3,000 shares of the business.
Shakil Ian sold 19,544 shares of AUGX for $74,590 on Apr 12 ’24. The CHIEF STRATEGY OFFICER now owns 3,000 shares after completing the transaction at $3.82 per share. On Apr 11 ’24, another insider, Shakil Ian, who serves as the CHIEF STRATEGY OFFICER of the company, sold 24,778 shares for $3.93 each. As a result, the insider received 97,477 and left with 3,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUGX now has a Market Capitalization of 114584416 and an Enterprise Value of 93679992. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.55 while its Price-to-Book (P/B) ratio in mrq is 4.88. Its current Enterprise Value per Revenue stands at 2.089 whereas that against EBITDA is -5.298.
Stock Price History:
The Beta on a monthly basis for AUGX is 0.46, which has changed by -0.3922078 over the last 52 weeks, in comparison to a change of 0.2704494 over the same period for the S&P500. Over the past 52 weeks, AUGX has reached a high of $6.25, while it has fallen to a 52-week low of $2.22. The 50-Day Moving Average of the stock is -32.75%, while the 200-Day Moving Average is calculated to be -49.18%.
Shares Statistics:
For the past three months, AUGX has traded an average of 379.87K shares per day and 409880 over the past ten days. A total of 48.61M shares are outstanding, with a floating share count of 43.96M. Insiders hold about 10.23% of the company’s shares, while institutions hold 74.70% stake in the company. Shares short for AUGX as of 1714435200 were 1688497 with a Short Ratio of 4.44, compared to 1711584000 on 831537. Therefore, it implies a Short% of Shares Outstanding of 1688497 and a Short% of Float of 6.41.
Earnings Estimates
The market rating for Augmedix Inc (AUGX) is a result of the insights provided by 5.0 analysts actively involved in the assessment.On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.17, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.44 and -$0.58 for the fiscal current year, implying an average EPS of -$0.51. EPS for the following year is -$0.35, with 4.0 analysts recommending between -$0.27 and -$0.44.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $13.37M this quarter.It ranges from a high estimate of $13.5M to a low estimate of $13.1M. As of the current estimate, Augmedix Inc’s year-ago sales were $9.63MFor the next quarter, 6 analysts are estimating revenue of $14.59M. There is a high estimate of $14.7M for the next quarter, whereas the lowest estimate is $14.4M.
A total of 6 analysts have provided revenue estimates for AUGX’s current fiscal year. The highest revenue estimate was $62M, while the lowest revenue estimate was $60.34M, resulting in an average revenue estimate of $61.15M. In the same quarter a year ago, actual revenue was $44.85MBased on 5 analysts’ estimates, the company’s revenue will be $85.1M in the next fiscal year. The high estimate is $87M and the low estimate is $83.39M.
